What the new CMA prescription fee cap means for your practice

If your practice currently charges more than £21 for a written prescription, the CMA's final remedies will require that fee to come down.

The cap is £21 for the first medicine prescribed within a consultation and £12.50 for each additional medicine in the same consultation, adjusted annually for inflation. For some practices, that will be a small compliance change. For others, it will expose a bigger commercial question: how much of the practice's current margin depends on clients continuing to buy long-term medication in-house?

That is the real planning issue. Not the £21 fee in isolation, but what happens when more clients are actively told they can request a prescription and may be able to buy medication more cheaply online.

The compliance date depends on the size of your business. For larger veterinary businesses (15 or more practice locations), the prescription fee cap comes into force in March 2027. For smaller independent practices with fewer than 15 locations, the deadline is September 2027. The CMA Order itself must be made by 23 September 2026, but that is a legislative deadline rather than a practice compliance date.

That gives smaller practices more time than some headlines suggest. It does not make the planning optional, and the revenue calculation is one worth running now rather than closer to the deadline.

This article covers what the cap means in practice, what the financial impact looks like for a typical independent clinic, and how to approach the formulary decisions and client conversations that follow. For a broader view of all 14 remedies and the concerns they are raising across the profession, Lupa's CVO Dr Nick Lloyd spoke with Pete Orpin, President of SPVS, who has been representing independent practices to the CMA throughout the process. It is a conversation worth watching.

What the cap actually covers

The cap applies only to the fee charged for providing a written prescription. It does not cap consultation fees, dispensing fees for medicines supplied in-house, vaccines, injections, surgery, or other clinical services.

The practical change is narrow, but important. When a client asks for a written prescription to use with an online pharmacy or another supplier, the practice will no longer be able to set that fee freely above the CMA cap.

Some practices have charged £40 or more for written prescriptions. The CMA's intention is to remove that barrier and make it easier for clients to compare medicine prices elsewhere. At the same time, practices will be required to tell clients that written prescriptions are available and that medicines may be significantly cheaper online.

The revenue impact: running the numbers

The financial effect depends entirely on what your practice currently charges and how many written prescriptions you issue.

For a practice charging £35 per prescription and issuing 15 written prescriptions per week, the cap reduces that income by £14 per prescription, or roughly £10,900 per year. That is the direct effect on prescription fee income alone. The secondary question is what happens to dispensing income as more clients use their written prescriptions to buy medication externally.

As Pete Orpin noted in his SPVS briefing with Lupa, medicines and prescriptions represent the biggest financial risk from the remedies package, potentially running into hundreds of thousands in lost revenue for practices that are unprepared. The CMA's own research found that independent practices tend to charge below the median, with many already charging under £20. If your practice is already at or below £21, the cap has limited direct financial impact. If it is above that, the calculation above is the one to do now.

The Federation of Independent Veterinary Practices has warned that more than 90% of independent vets believe a shift to online pharmacies will affect their ability to provide services. That concern is not irrational. Practices that rely on medicines margin to cross-subsidise consultation fees or staff costs will feel the effect of reduced dispensing volume, regardless of where the prescription fee is set. Our article on how to price veterinary services after the CMA regulations covers the broader revenue strategy in detail.

Dr Nick Lloyd on what the cap means in practice

The £21 cap is reasonable for the time involved. It should encourage practices to develop more efficient processes, and that is not a bad thing. Some practices have been charging £40 or more for a written prescription. That created a genuine barrier to client choice, and it needed to change.

The bigger concern is not the fee itself. It is what it unlocks downstream. A lower prescription fee makes it easier for clients to buy medication elsewhere. Independent practices tend to rely more on medicines margin to cross-subsidise clinical time than corporate groups do. That is the real financial risk, and it is worth naming directly.

My view: fair in intent, blunt in execution. The right response is to adapt the business model, not resist the regulation.

Which medicines are most at risk of moving online

High-volume, long-term medications for chronic conditions like thyroid management, joint disease and diabetic care are the products most likely to migrate online once the prescription barrier is lower. If your practice carries significant stock of these, the carrying cost relative to likely dispensing volume after the cap warrants a fresh look.

Short-course, acute medications and drugs required immediately in a clinical context are less vulnerable. Controlled drugs, medications requiring cold chain management, and products needing specific dispensing guidance are similarly less affected.

The formulary review does not need to produce dramatic change for most practices. It needs to produce a clear-eyed view of which products earn their stock position at the volumes you are likely to see post-cap, and which have been carried optimistically. Lupa's dispensing and stock management tools make it straightforward to run that analysis from your existing records.

Dr Lloyd is direct on the priority: "The issue is not really the cap. It is the potential loss of drug sales. Run your numbers on chronic condition medications before the deadline: thyroid, diabetes, joint disease. Identify which products you stock primarily because clients buy them from you, versus which ones you genuinely need in-house. Then model what happens to your P&L if you lose 20%, 50%, or 80% of that dispensing. If you have a plan before the deadline, the compliance date becomes manageable. If you are still working that out in August 2027, it will be painful."

The client conversation

The cap changes what a practice is required to tell clients, and it changes the dynamics of a conversation that many vets have been navigating carefully for years.

From the compliance date, practices must proactively inform clients that a written prescription is available and that medicines may be significantly cheaper to purchase online. That disclosure is mandatory regardless of whether the client asks.

For most clients, the conversation will be unremarkable. Many already know they can buy medication elsewhere. For a smaller number, it will be new information, and the way the practice handles it will shape how they feel about their relationship with you.

The instinct to treat the disclosure as a compliance obligation, something said quickly and without warmth, is understandable but counterproductive. A client told clearly and without embarrassment that they have options is more likely to trust the practice and less likely to feel they have been overcharged in the past. The message is not "we are required to tell you that you can buy medication elsewhere." It is "we want you to have the most cost-effective option for Bella's long-term medication. Here is a written prescription and here is what to look for if you shop around."

Dr Lloyd describes the shift plainly: "At the moment it is mostly reactive. A client asks, I provide the prescription, sometimes with apologetic language that actually undermines trust. The bigger shift will be proactively raising that conversation as part of the clinical handoff, rather than waiting to be asked. Technology will also accelerate this faster than the regulation alone. In the near future, sending prescriptions directly to pharmacies, showing comparative prices at the point of consultation, or directing clients to an in-house home delivery service should all be possible. Practices that lean into that will come out with more client trust, not less."

Dr Nick Lloyd and Flo Page from Vetsure covered exactly this dynamic in their joint session on health plans, pricing strategy, and CMA preparation, including how to help your team discuss pricing confidently without apologetic language. It is worth watching alongside this article.

The practices that handle this transition well will frame the disclosure as patient-centred. That framing is also, not incidentally, the one that protects the client relationship.

What to do before your compliance date

Start with the fee itself. If you charge above £21, run the annual revenue calculation now so the number is not a surprise when the deadline arrives. For larger businesses the cap lands in March 2027; for independents it is September 2027. That is more runway than some headlines suggest, but formulary and pricing decisions made close to the deadline will be more disruptive than ones made earlier.

Then look at your formulary. Which chronic condition medications are genuinely needed in-house, and which are stocked primarily because clients currently buy them from you? Model the impact on your P&L if 20%, 50%, or 80% of that dispensing moves online. The products to focus on are thyroid, diabetes, and joint disease: high volume, repeat prescription, and exactly the category most likely to migrate once the prescription barrier is lower.

Prepare your team for the disclosure conversation before it becomes a live requirement. The wording is not prescribed by the CMA, so draft a version that feels natural for your practice and brief your clinical staff before anyone is caught off-guard by a client who already knows about the cap. The framing matters: a client told clearly that they have options is more likely to trust the practice, not less.

One wider point: the prescription fee is one line in a broader pricing review that most practices need to do regardless. The price list publication requirement lands earlier, between December 2026 and March 2027 depending on practice size, making that the more pressing near-term task.

For a step-by-step guide to preparing your practice for the earlier pricing transparency requirements, read CMA pricing transparency: how to update your practice before the September deadline.

To see how Lupa OS supports pricing transparency, client communications, and itemised billing as part of a connected workflow, book a demo.